Lipid and vascular biomarker responses to sulfated chitosan in rabbits with experimental hypercholesterolemia

Sulfation modifies the biological properties of chitosan and may produce compounds with activity relevant to vascular disease. The efficacy of an individual preparation requires evaluation independently of findings for other chitosan derivatives. Objective: To describe the lipid and circulating vascular biomarker responses associated with a locally synthesized sulfated chitosan preparation, designated sulfoparin, in cholesterol-exposed rabbits. Methods: Aggregate endpoint data were extracted from a dissertation reporting 46 Chinchilla rabbits allocated to an intact group (n = 6) and five cholesterol-exposed groups (n = 8 each). After two months of cholesterol exposure, treatment continued for one month alongside cholesterol administration. Groups received no active treatment, a fibrate comparator reported as “hemfibrazil” at 100 mg/kg, heparin at 15 IU/kg, or sulfated chitosan at reported doses of 25 or 50 μg/kg. Treatment routes and the unusually low chitosan dose units require verification. Results: Compared descriptively with untreated hypercholesterolemia, sulfated chitosan at the two reported doses was associated with 53.9% and 55.4% lower total cholesterol, 71.7% and 74.4% lower LDL cholesterol, and 73.1% and 78.3% lower C-reactive protein. NOx was 12.29 and 17.86 μmol/L, respectively, compared with 7.89 μmol/L in untreated animals and 16.68 μmol/L in intact animals. Homocysteine remained numerically above the intact reference at both doses. No new inferential statistics were calculated. Conclusions: The source tables describe substantial lipid and biomarker differences associated with sulfated chitosan treatment. These findings support confirmatory investigation but do not establish clinical efficacy, equivalence to heparin, functional endothelial recovery or an optimal dose. Verification of the compound, dosing records, assays and raw data is essential.